Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up

Authors: Tomás Merino, Ignacio F San Francisco, Pablo A Rojas, Piero Bettoli, Álvaro Zúñiga, Pelayo Besa

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The objective of this work was to assess the overall survival, cause-specific survival and biochemical failure-free survival of a contemporary cohort of patients with localized prostate cancer (PCa) treated with intensity-modulated radiation therapy (IMRT) or radical prostatectomy (RP).

Methods

We did a retrospective cohort study of our institution’s registry of patients undergoing either IMRT or RP between January 1999 and March 2010, and assessed Prostate Specific Antigen (PSA), age at diagnosis, Gleason score, and digital rectal examination. Two groups were separated according to RP or IMRT treatment and these groups were in turn divided into risk groups according to the D’Amico classification. Overall survival (OS), cause-specific survival (CSS), mortality from other causes (MOC), and biochemical disease-free survival (BDFS) were assessed.

Results

Twelve-hundred patients were included: 993 in the RP group and 207 in the IMRT group.
The IMRT group had older age, PSA at diagnosis and a significantly higher percentage of cancer on the needle biopsy (p <0.001). Of the 207 patients who underwent IMRT, 54% presented comorbidities. Median follow-up was 91.7 months for the RP group and 76 months for the IMRT group. The OS at 5 and 7 was 96.2, and 93.7 for the RP group respectively and 88.4, and 83.1 for the IMRT group respectively (p <0.001). There were no significant differences in the CSS in relation to treatment received among the low- and high-risk groups, while in the intermediate-risk group, patients who underwent to RP had a higher CSS than patients who underwent IMRT (99.6% vs 94.1%, p = 0.003). The IMRT group had a significantly better BDFS than the RP group (86.4% vs. 74.3%, respectively, p = 0.016).

Conclusions

Patients treated with RP were significantly younger and had a better prognosis than patients treated using IMRT, and according to our results, RP had better outcomes in terms of OS while IMRT had greater MOC. Treatment modality did not affect the CSS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
go back to reference Ministerio de Salud: Guía Clínica Cáncer de Próstata en Personas de 15 años y mas. Serie Guías Clínicas Minsal N° 34. 2006, Santiago: Minsal, 1 Ministerio de Salud: Guía Clínica Cáncer de Próstata en Personas de 15 años y mas. Serie Guías Clínicas Minsal N° 34. 2006, Santiago: Minsal, 1
3.
go back to reference Corti D: Epidemiología del Cáncer de Próstata, Provincia de Valdivia, 1990-2000. Rev Chil Uro. 2002, 63 (2): 211-214. Corti D: Epidemiología del Cáncer de Próstata, Provincia de Valdivia, 1990-2000. Rev Chil Uro. 2002, 63 (2): 211-214.
4.
go back to reference Baechler R: Prevalencia del cáncer de próstata en la comuna de Talca, VII región Chile. Rev Med Chile. 2001, 129: 1305-10.CrossRefPubMed Baechler R: Prevalencia del cáncer de próstata en la comuna de Talca, VII región Chile. Rev Med Chile. 2001, 129: 1305-10.CrossRefPubMed
5.
go back to reference Kupelian PA: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004, 58 (1): 25-33. 10.1016/S0360-3016(03)00784-3.CrossRefPubMed Kupelian PA: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004, 58 (1): 25-33. 10.1016/S0360-3016(03)00784-3.CrossRefPubMed
6.
go back to reference Potosky AL: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004, 96: 1358-1367. 10.1093/jnci/djh259.CrossRefPubMed Potosky AL: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004, 96: 1358-1367. 10.1093/jnci/djh259.CrossRefPubMed
7.
go back to reference D’Amico AV: Biochemical outcome after prostatectomy external beam radiation therapy or intersticial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 28 (11): 969-976.CrossRef D’Amico AV: Biochemical outcome after prostatectomy external beam radiation therapy or intersticial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 28 (11): 969-976.CrossRef
8.
go back to reference Chou R, Dana T, Bougatsos C, et al: Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet]. 2011, Rockville (MD): Agency for Healthcare Research and Quality (US), Oct. (Evidence Syntheses, No. 91.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK82315/ Chou R, Dana T, Bougatsos C, et al: Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet]. 2011, Rockville (MD): Agency for Healthcare Research and Quality (US), Oct. (Evidence Syntheses, No. 91.) Available from: http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK82315/​
9.
go back to reference Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL: Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008, 148 (6): 435-448. 10.7326/0003-4819-148-6-200803180-00209.CrossRefPubMed Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL: Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008, 148 (6): 435-448. 10.7326/0003-4819-148-6-200803180-00209.CrossRefPubMed
10.
go back to reference Sheets NC, Goldin GH, Meyer AM, et al: Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012, 307 (15): 1611-1620. 10.1001/jama.2012.460.CrossRefPubMedPubMedCentral Sheets NC, Goldin GH, Meyer AM, et al: Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012, 307 (15): 1611-1620. 10.1001/jama.2012.460.CrossRefPubMedPubMedCentral
11.
go back to reference Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A: Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2010, 14 (47): 1-108.CrossRefPubMed Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A: Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2010, 14 (47): 1-108.CrossRefPubMed
12.
go back to reference Bannuru RR, Dvorak T, Obadan N, Yu WW, Patel K, Chung M, Ip S: Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann Intern Med. 2011, 155 (3): 171-178. 10.7326/0003-4819-155-3-201108020-00347.CrossRefPubMed Bannuru RR, Dvorak T, Obadan N, Yu WW, Patel K, Chung M, Ip S: Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann Intern Med. 2011, 155 (3): 171-178. 10.7326/0003-4819-155-3-201108020-00347.CrossRefPubMed
13.
go back to reference Bauman G, Rumble RB, Chen J, Loblawx A, Warde P: Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol. 2012, 24: 461-473. 10.1016/j.clon.2012.05.002.CrossRef Bauman G, Rumble RB, Chen J, Loblawx A, Warde P: Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol. 2012, 24: 461-473. 10.1016/j.clon.2012.05.002.CrossRef
14.
go back to reference Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE: Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009, 93 (2): 185-191. 10.1016/j.radonc.2009.09.001.CrossRefPubMed Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE: Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009, 93 (2): 185-191. 10.1016/j.radonc.2009.09.001.CrossRefPubMed
15.
go back to reference Mohler J, Bahnson RR, Boston B, et al: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010, 8 (2): 162-200.PubMed Mohler J, Bahnson RR, Boston B, et al: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010, 8 (2): 162-200.PubMed
16.
go back to reference D’Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280: 969-975. 10.1001/jama.280.11.969.CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280: 969-975. 10.1001/jama.280.11.969.CrossRefPubMed
17.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
18.
go back to reference Washigton, DC: International Commission on Radiation Units and Measurements: ICRU Report 62. Prescribing, Recording and Reporting Photon Beam Therapy. 1999, Supplement to ICRU Report 50 Washigton, DC: International Commission on Radiation Units and Measurements: ICRU Report 62. Prescribing, Recording and Reporting Photon Beam Therapy. 1999, Supplement to ICRU Report 50
19.
go back to reference Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006, 65 (4): 965-974. 10.1016/j.ijrobp.2006.04.029.CrossRefPubMed Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006, 65 (4): 965-974. 10.1016/j.ijrobp.2006.04.029.CrossRefPubMed
20.
go back to reference Abdollah F, Schmitges J, Sun M, et al: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol. 2012, 19: 836-844. 10.1111/j.1442-2042.2012.03052.x.CrossRefPubMed Abdollah F, Schmitges J, Sun M, et al: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol. 2012, 19: 836-844. 10.1111/j.1442-2042.2012.03052.x.CrossRefPubMed
21.
go back to reference Schymura MJ, Kahn AR, German RR, et al: Factorseassociated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR patterns of care study. BMC Cancer. 2010, 10: 152-10.1186/1471-2407-10-152.CrossRefPubMedPubMedCentral Schymura MJ, Kahn AR, German RR, et al: Factorseassociated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR patterns of care study. BMC Cancer. 2010, 10: 152-10.1186/1471-2407-10-152.CrossRefPubMedPubMedCentral
22.
go back to reference Dinan MA, Robinson TJ, Zagar TM, Scales CD, Curtis LH, Reed SD, Lee WR, Schulman KA: Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999e2007. Int J Radiation Oncol Biol Phys. 2012, 82 (5): 781-786. 10.1016/j.ijrobp.2011.11.024.CrossRef Dinan MA, Robinson TJ, Zagar TM, Scales CD, Curtis LH, Reed SD, Lee WR, Schulman KA: Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999e2007. Int J Radiation Oncol Biol Phys. 2012, 82 (5): 781-786. 10.1016/j.ijrobp.2011.11.024.CrossRef
23.
go back to reference Besa P, Rosso R, Bustos M, Borghero Y, Trucco C, Mac-Namara M: Intensity modulated radiotherapy treatment for prostate cancer, first experience in Chile. Rev Med Chile. 2011, 139: 1451-1457. 10.4067/S0034-98872011001100009.CrossRef Besa P, Rosso R, Bustos M, Borghero Y, Trucco C, Mac-Namara M: Intensity modulated radiotherapy treatment for prostate cancer, first experience in Chile. Rev Med Chile. 2011, 139: 1451-1457. 10.4067/S0034-98872011001100009.CrossRef
24.
go back to reference Parikh R, Sher DJ: Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis. Cancer. 2012, 118 (1): 258-267. 10.1002/cncr.26272.CrossRefPubMed Parikh R, Sher DJ: Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis. Cancer. 2012, 118 (1): 258-267. 10.1002/cncr.26272.CrossRefPubMed
25.
go back to reference Horwitz EM, Bae K, Hanks GE, et al: Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008, 26 (15): 2497-2504. 10.1200/JCO.2007.14.9021.CrossRefPubMed Horwitz EM, Bae K, Hanks GE, et al: Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008, 26 (15): 2497-2504. 10.1200/JCO.2007.14.9021.CrossRefPubMed
26.
go back to reference Bolla M, de Reijke TM, Van Tienhoven G, et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009, 360 (24): 2516-2527. 10.1056/NEJMoa0810095.CrossRefPubMed Bolla M, de Reijke TM, Van Tienhoven G, et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009, 360 (24): 2516-2527. 10.1056/NEJMoa0810095.CrossRefPubMed
27.
go back to reference Bolla M, Van Tienhoven G, Warde P, et al: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010, 11 (11): 1066-1073. 10.1016/S1470-2045(10)70223-0.CrossRefPubMed Bolla M, Van Tienhoven G, Warde P, et al: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010, 11 (11): 1066-1073. 10.1016/S1470-2045(10)70223-0.CrossRefPubMed
28.
go back to reference Morikawa LK, Roach M: Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011, 80 (1): 6-16. 10.1016/j.ijrobp.2010.11.074.CrossRefPubMed Morikawa LK, Roach M: Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011, 80 (1): 6-16. 10.1016/j.ijrobp.2010.11.074.CrossRefPubMed
Metadata
Title
Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up
Authors
Tomás Merino
Ignacio F San Francisco
Pablo A Rojas
Piero Bettoli
Álvaro Zúñiga
Pelayo Besa
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-530

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine